Patient derived xenografts (PDX) are models of cancer where the tissue or cells from a patient's tumor are implanted into an immunodeficient or humanized mouse. PDX models are used to create an environment that allows for the natural growth of cancer, its monitoring, and corresponding treatment evaluations for the original patient.
Highlights
The global Patient Derived Xenograft & PDX Models market was valued at US$ 364 million in 2022 and is anticipated to reach US$ 593.9 million by 2029, witnessing a CAGR of 8.5% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Global top 5 manufacturers of patient-derived xenograft (PDX) models occupied for a share nearly 45 percent, key players are Crown Bioscience, Champions Oncology, Wuxi Apptec, EPO Berlin-Buch, and Oncodesign, etc. Geographically speaking, Asia Pacific holds the most of global market share, about 35%. North America holds about 30% of share, while Europe followed by nearly 20%. In terms of type, mouse model accounted for nearly 75%, and rat model accounted for a share of 25%,The application of patient-derived xenograft (PDX) models includes preclinical drug development and biomarker analysis. Preclinical drug development shares over 75%, while biomarker analysis shares about 20%.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Patient Derived Xenograft & PDX Models, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Patient Derived Xenograft & PDX Models.
The Patient Derived Xenograft & PDX Models market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Patient Derived Xenograft & PDX Models market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Patient Derived Xenograft & PDX Models companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Crown Bioscience
The Jackson Laboratory
Champions Oncology
Charles River Laboratories
WuXi Apptec
Oncodesign
Horizon Discovery
Pharmatest Services
Hera Biolabs
EPO Berlin-Buch
Xentech
Urolead
Segment by Type
Mice Models
Rat Models
Segment by Application
Pre-clinical Drug Development and Basic Cancer Research
Biomarker Analysis
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Patient Derived Xenograft & PDX Models companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Patient Derived Xenograft & PDX Models Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Mice Models
1.2.3 Rat Models
1.3 Market by Application
1.3.1 Global Patient Derived Xenograft & PDX Models Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Pre-clinical Drug Development and Basic Cancer Research
1.3.3 Biomarker Analysis
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Patient Derived Xenograft & PDX Models Market Perspective (2018-2029)
2.2 Patient Derived Xenograft & PDX Models Growth Trends by Region
2.2.1 Global Patient Derived Xenograft & PDX Models Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Patient Derived Xenograft & PDX Models Historic Market Size by Region (2018-2023)
2.2.3 Patient Derived Xenograft & PDX Models Forecasted Market Size by Region (2024-2029)
2.3 Patient Derived Xenograft & PDX Models Market Dynamics
2.3.1 Patient Derived Xenograft & PDX Models Industry Trends
2.3.2 Patient Derived Xenograft & PDX Models Market Drivers
2.3.3 Patient Derived Xenograft & PDX Models Market Challenges
2.3.4 Patient Derived Xenograft & PDX Models Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Patient Derived Xenograft & PDX Models Players by Revenue
3.1.1 Global Top Patient Derived Xenograft & PDX Models Players by Revenue (2018-2023)
3.1.2 Global Patient Derived Xenograft & PDX Models Revenue Market Share by Players (2018-2023)
3.2 Global Patient Derived Xenograft & PDX Models Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Patient Derived Xenograft & PDX Models Revenue
3.4 Global Patient Derived Xenograft & PDX Models Market Concentration Ratio
3.4.1 Global Patient Derived Xenograft & PDX Models Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Patient Derived Xenograft & PDX Models Revenue in 2022
3.5 Patient Derived Xenograft & PDX Models Key Players Head office and Area Served
3.6 Key Players Patient Derived Xenograft & PDX Models Product Solution and Service
3.7 Date of Enter into Patient Derived Xenograft & PDX Models Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Patient Derived Xenograft & PDX Models Breakdown Data by Type
4.1 Global Patient Derived Xenograft & PDX Models Historic Market Size by Type (2018-2023)
4.2 Global Patient Derived Xenograft & PDX Models Forecasted Market Size by Type (2024-2029)
5 Patient Derived Xenograft & PDX Models Breakdown Data by Application
5.1 Global Patient Derived Xenograft & PDX Models Historic Market Size by Application (2018-2023)
5.2 Global Patient Derived Xenograft & PDX Models Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Patient Derived Xenograft & PDX Models Market Size (2018-2029)
6.2 North America Patient Derived Xenograft & PDX Models Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Patient Derived Xenograft & PDX Models Market Size by Country (2018-2023)
6.4 North America Patient Derived Xenograft & PDX Models Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Patient Derived Xenograft & PDX Models Market Size (2018-2029)
7.2 Europe Patient Derived Xenograft & PDX Models Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Patient Derived Xenograft & PDX Models Market Size by Country (2018-2023)
7.4 Europe Patient Derived Xenograft & PDX Models Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Patient Derived Xenograft & PDX Models Market Size (2018-2029)
8.2 Asia-Pacific Patient Derived Xenograft & PDX Models Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Patient Derived Xenograft & PDX Models Market Size by Region (2018-2023)
8.4 Asia-Pacific Patient Derived Xenograft & PDX Models Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Patient Derived Xenograft & PDX Models Market Size (2018-2029)
9.2 Latin America Patient Derived Xenograft & PDX Models Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Patient Derived Xenograft & PDX Models Market Size by Country (2018-2023)
9.4 Latin America Patient Derived Xenograft & PDX Models Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Patient Derived Xenograft & PDX Models Market Size (2018-2029)
10.2 Middle East & Africa Patient Derived Xenograft & PDX Models Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Patient Derived Xenograft & PDX Models Market Size by Country (2018-2023)
10.4 Middle East & Africa Patient Derived Xenograft & PDX Models Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Crown Bioscience
11.1.1 Crown Bioscience Company Detail
11.1.2 Crown Bioscience Business Overview
11.1.3 Crown Bioscience Patient Derived Xenograft & PDX Models Introduction
11.1.4 Crown Bioscience Revenue in Patient Derived Xenograft & PDX Models Business (2018-2023)
11.1.5 Crown Bioscience Recent Development
11.2 The Jackson Laboratory
11.2.1 The Jackson Laboratory Company Detail
11.2.2 The Jackson Laboratory Business Overview
11.2.3 The Jackson Laboratory Patient Derived Xenograft & PDX Models Introduction
11.2.4 The Jackson Laboratory Revenue in Patient Derived Xenograft & PDX Models Business (2018-2023)
11.2.5 The Jackson Laboratory Recent Development
11.3 Champions Oncology
11.3.1 Champions Oncology Company Detail
11.3.2 Champions Oncology Business Overview
11.3.3 Champions Oncology Patient Derived Xenograft & PDX Models Introduction
11.3.4 Champions Oncology Revenue in Patient Derived Xenograft & PDX Models Business (2018-2023)
11.3.5 Champions Oncology Recent Development
11.4 Charles River Laboratories
11.4.1 Charles River Laboratories Company Detail
11.4.2 Charles River Laboratories Business Overview
11.4.3 Charles River Laboratories Patient Derived Xenograft & PDX Models Introduction
11.4.4 Charles River Laboratories Revenue in Patient Derived Xenograft & PDX Models Business (2018-2023)
11.4.5 Charles River Laboratories Recent Development
11.5 WuXi Apptec
11.5.1 WuXi Apptec Company Detail
11.5.2 WuXi Apptec Business Overview
11.5.3 WuXi Apptec Patient Derived Xenograft & PDX Models Introduction
11.5.4 WuXi Apptec Revenue in Patient Derived Xenograft & PDX Models Business (2018-2023)
11.5.5 WuXi Apptec Recent Development
11.6 Oncodesign
11.6.1 Oncodesign Company Detail
11.6.2 Oncodesign Business Overview
11.6.3 Oncodesign Patient Derived Xenograft & PDX Models Introduction
11.6.4 Oncodesign Revenue in Patient Derived Xenograft & PDX Models Business (2018-2023)
11.6.5 Oncodesign Recent Development
11.7 Horizon Discovery
11.7.1 Horizon Discovery Company Detail
11.7.2 Horizon Discovery Business Overview
11.7.3 Horizon Discovery Patient Derived Xenograft & PDX Models Introduction
11.7.4 Horizon Discovery Revenue in Patient Derived Xenograft & PDX Models Business (2018-2023)
11.7.5 Horizon Discovery Recent Development
11.8 Pharmatest Services
11.8.1 Pharmatest Services Company Detail
11.8.2 Pharmatest Services Business Overview
11.8.3 Pharmatest Services Patient Derived Xenograft & PDX Models Introduction
11.8.4 Pharmatest Services Revenue in Patient Derived Xenograft & PDX Models Business (2018-2023)
11.8.5 Pharmatest Services Recent Development
11.9 Hera Biolabs
11.9.1 Hera Biolabs Company Detail
11.9.2 Hera Biolabs Business Overview
11.9.3 Hera Biolabs Patient Derived Xenograft & PDX Models Introduction
11.9.4 Hera Biolabs Revenue in Patient Derived Xenograft & PDX Models Business (2018-2023)
11.9.5 Hera Biolabs Recent Development
11.10 EPO Berlin-Buch
11.10.1 EPO Berlin-Buch Company Detail
11.10.2 EPO Berlin-Buch Business Overview
11.10.3 EPO Berlin-Buch Patient Derived Xenograft & PDX Models Introduction
11.10.4 EPO Berlin-Buch Revenue in Patient Derived Xenograft & PDX Models Business (2018-2023)
11.10.5 EPO Berlin-Buch Recent Development
11.11 Xentech
11.11.1 Xentech Company Detail
11.11.2 Xentech Business Overview
11.11.3 Xentech Patient Derived Xenograft & PDX Models Introduction
11.11.4 Xentech Revenue in Patient Derived Xenograft & PDX Models Business (2018-2023)
11.11.5 Xentech Recent Development
11.12 Urolead
11.12.1 Urolead Company Detail
11.12.2 Urolead Business Overview
11.12.3 Urolead Patient Derived Xenograft & PDX Models Introduction
11.12.4 Urolead Revenue in Patient Derived Xenograft & PDX Models Business (2018-2023)
11.12.5 Urolead Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Crown Bioscience
The Jackson Laboratory
Champions Oncology
Charles River Laboratories
WuXi Apptec
Oncodesign
Horizon Discovery
Pharmatest Services
Hera Biolabs
EPO Berlin-Buch
Xentech
Urolead
听
听
*If Applicable.
